Adicet Bio said the FDA cleared its IND for ADI-212, setting up early clinical evaluation in patients with metastatic castration-resistant prostate cancer (mCRPC). The clearance provides regulatory authorization to start studies after preclinical and investigative-planning submissions. While the release does not detail efficacy outcomes, the IND nod marks a concrete pipeline milestone for a company operating in the prostate cancer space. For the broader androgen-resistant prostate cancer landscape, new IND clearances help maintain development momentum as prior generations of therapies increasingly face resistance. The next steps will hinge on trial design, dose escalation approach, and target validation in mCRPC cohorts.